# of Displayed Technologies: 40 / 151

Applied Category Filter (Click To Remove): Clinical Area


Categories

Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
  • College: College of Medicine (COM)
  • Inventors: Kerur, Nagaraj
  • Licensing Officer: Schultz, Teri

Treating Diabetes, Obesity, and Cardiovascular Disease by Reprogramming Skin
TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health
The incidence of obesity and diabetes is skyrocketing, leading to chronic inflammatory conditions such as cardiovascular disease, autoimmune diseases, liver diseases, and cancer. Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all ad…
  • College: College of Medicine (COM)
  • Inventors: Gallego Perez, Daniel; Higuita Castro, Natalia; Sen, Chandan
  • Licensing Officer: Schultz, Teri

Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes. The Need Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
  • College: College of Medicine (COM)
  • Inventors: Kaumaya, Pravin
  • Licensing Officer: Schultz, Teri

Targeted Nanobody Technology for Precise Antineoplastic Treatment
TS-065460 — The Need Cancer remains one of the most pressing medical challenges worldwide, necessitating novel therapeutic approaches to combat its proliferation. Despite advancements, targeted therapies are often limited by immune responses or cumbersome production processes. There's a growing demand for …
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Palmieri, Dario; Ryan-Simkins, Michael
  • Licensing Officer: Willson, Christopher

Peptide-based inhibitor of host factor involved in HIV-1 replication
TS-065459 — The Need The emergence of HIV-1 infection continues to pose significant challenges in healthcare worldwide. Current treatment approaches primarily target viral components, leading to the development of drug resistance over time. There is a pressing need for innovative therapeutic strategies that di…
  • College: College of Arts & Sciences
  • Inventors: Musier-Forsyth, Karin; Tang, Yingke
  • Licensing Officer: Willson, Christopher

Precision RNA-PROTACs: Revolutionizing Therapeutic Targeting of Dysregulated Ribonucleoprotein Complexes
TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…
  • College: College of Arts & Sciences
  • Inventors: Bong, Dennis; Liang, Yufeng; Miao, Shiqin "Shiqin"; Strong, Rebekah
  • Licensing Officer: Willson, Christopher

MicroRNA profile predicts colon cancer prognosis
TS-065453 — The Need: Colon cancer remains one of the most prevalent and lethal forms of cancer worldwide. Timely and accurate diagnosis is critical for effective treatment and improved patient outcomes. Current diagnostic methods often lack the precision and sensitivity needed for early detection and prognosi…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo
  • Licensing Officer: Dahlman, Jason "Jay"

Novel Extracellular Vesicles Loaded with Anti-Inflammatory Agents
TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.
The Need Acute Respiratory Distress Syndrome (ARDS) remains a significant healthcare challenge with high mortality rates and long-term morbidity. Despite advancements in supportive care, there’s an urgent need for pharmacologic treatments targeting the molecular mechanisms driving ARDS pathog…
  • College: College of Medicine (COM)
  • Inventors: Karpurapu, Manjula; Christman, John; Parinandi, Narasimham
  • Licensing Officer: Schultz, Teri

Unveiling Unreported Pain: A Systematic Approach for Enhanced Patient Care
TS-064835 — The Need In healthcare, accurately assessing and managing pain is paramount for patient well-being and treatment efficacy. However, conventional methods of pain assessment rely heavily on verbal communication from patients, which poses challenges for individuals unable to express their pain verball…
  • College: College of Nursing
  • Inventors: Monroe, Todd
  • Licensing Officer: Wilburn, Adri

Intracellular Targeting by Monoclonal Antibodies
TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
  • Licensing Officer: Willson, Christopher

Magnetic Nanoparticles for Cancer Cell Classification
TS-064577 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately only 40% living past the first-year post-diagnosis and 17% in the second year. The Need Developing drugs for cance…
  • College: College of Arts & Sciences
  • Inventors: Schultz, Zachary; Rist, David; Skardal, Aleksander; Venere, Monica
  • Licensing Officer: Willson, Christopher

Utilizing WT-IV-012 to improve immune checkpoint therapy in cancer treatment
TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…
  • College: College of Arts & Sciences
  • Inventors: Burd, Craig; Aguilar-Valenzuela, Renan; Burd, Christin
  • Licensing Officer: Willson, Christopher

Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: OSU Wexner Medical Center
  • Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
  • Licensing Officer: Willson, Christopher

How Are You Feeling Today? Organizational Mental Health Indicator and Real-Time Help Application
TS-064244 — The Need: Organizations, particularly college campuses, are facing a growing challenge in addressing student mental health issues. The rising prevalence of severe psychological problems, anxiety disorders, and depression among students necessitates a proactive and effective solution. The existing ga…
  • College: College of Engineering (COE)
  • Inventors: Ezell, Jonathan; Kaufman, Michael
  • Licensing Officer: Dahlman, Jason "Jay"

CDP-choline a host-directed therapeutic for disease caused by SARS CoV-2 infection.
TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…
  • College: College of Veterinary Medicine
  • Inventors: Davis, Ian; Schelhorn, Jean
  • Licensing Officer: Dahlman, Jason "Jay"

Introducing HexaPro VSV: A Breakthrough in COVID-19 Vaccine Technology
TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Chamblee, Michelle; Lu, Mijia; Zhang, Yuexiu
  • Licensing Officer: Dahlman, Jason "Jay"

A new diagnostic assay for classic galactosemia
TS-064133 — Classic galactosemia is a genetic condition that can lead to life-threatening complications, including feeding problems, failure to thrive, liver damage, bleeding, and sepsis. If a lactose-restricted diet is provided during the first ten days of life, the neonatal symptoms quickly resolve and reduce…
  • College: College of Arts & Sciences
  • Inventors: Gopalan, Venkat; Bashian, Eleanor; Thirugnanasambantham, Pankajavalli
  • Licensing Officer: Willson, Christopher

Skin Healing Technology: Dermal Substitutes and Engineered Skin with Rete Ridges
TS-064046 — Dermal substitute with engineered rete ridges improves epidermal-dermal communication and enhances burn wound treatment.
Massive burn injuries present a critical challenge in wound healing and prevention of infection. Current treatment methods are susceptible to blistering and other problems that can reduce engraftment. The Need Cultured epithelial autografts (CEAs) are a vital component in treating large burns, but…
  • College: College of Engineering (COE)
  • Inventors: Powell, Heather; Bailey, John; Blackstone, Britani "Niki"
  • Licensing Officer: Schultz, Teri

Adjustable Squatting Device for Constipation
TS-063959 — The Need Millions of individuals suffer from constipation due to the inability to relax pelvic floor muscles during bowel movements, leading to discomfort and strained efforts. Current solutions, like the Squatty Potty, lack adjustability and portability, limiting their effectiveness for a diverse …
  • College: College of Engineering (COE)
  • Inventors: Ruegsegger, Mark; Chakraborty, Subhankar; Gluzman, Isabella; Li, Yiqun; Piatkowski, Stephen; Puri, Raima
  • Licensing Officer: Bhatti, Hamid

Endoscopic additive manufacturing of biomaterials
TS-063919 — An articulating end effector for additive manufacturing that utilizes robot-assisted endoscopic surgery to implant synthetic tissues at local defects through “keyhole” incisions in patients. This innovative technology T2019-145 is part of a portfolio that also includes T2017-363. To learn more about both technologies, please visit https://oied.osu.edu/find-technologies and search using the phrase: Endoscopic additive manufacturing of biomaterials.
Robot-assisted surgery, tissue engineering, and additive manufacturing (AM) are emerging techniques in healthcare. Currently AM is used to develop synthetic tissues and organs, but open surgery is typically used to implant these scaffolds within the patient. This invasive procedure can subject pat…
  • College: College of Engineering (COE)
  • Inventors: Hoelzle, David; Asghari Adib, Ali; D'Souza, Desmond; Mansour, Daniel; Simeunovic, Andrej
  • Licensing Officer: Zinn, Ryan

Novel STK1-targeted small molecule "antibiotic resistance breaker" compounds
TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.
In today’s healthcare landscape, increasingly highly pathogenic and multidrug-resistant S. aureus (MDRSA) strains are replacing traditional methicillin-resistant S. aureus (MRSA) in both community and hospital settings. The Need The rise of these resilient multi-drug resistant bacteria has …
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Schultz, Teri

Protecting the vascular endothelial barrier – a novel approach to treating atrial fibrillation
TS-063433 — A new pharmacologic modality for treating AFib.
Atrial fibrillation (AF) is the most common form of irregular cardiac rhythm (arrhythmia), affecting approximately 3% of the US population. It is a significant risk factor for heart failure, ischemic stroke, and sudden cardiac death. The AF mortality rate is growing globally, and risk factors known …
  • College: College of Engineering (COE)
  • Inventors: Veeraraghavan, Rengasayee; Mezache, Louisa
  • Licensing Officer: Schultz, Teri

Convolutional Neural Network to Assess Phayngeal and Laryngeal Pathology and Function on Nasopharyngolaryngoscopy
TS-063154 — Worldwide, 686,000 new head and neck (H&N) cancers are diagnosed yearly, and 375,000 people will die annually. Human papillomavirus (HPV) is responsible for an increasing subset of H&N malignancies called oropharyngeal squamous cell carcinomas (OPSCC). Although it has a better prognosis than…
  • College: College of Engineering (COE)
  • Inventors: Krening, Samantha; Gifford, Ryan; Jhawar, Sachin; VanKoevering, Kyle
  • Licensing Officer: Hampton, Andrew

Gene Therapy Compositions for Treating Cardiovascular Diseases
TS-063091 — A gene therapy approach to address the specific needs of failing hearts.
Heart failure affects over 6 million adults in the US and can lead to irreversible damage to the heart. The Need In the realm of cardiovascular health and the management of heart-related disorders, there exists a pressing commercial need for a technology that can effectively address the challenge…
  • College: College of Medicine (COM)
  • Inventors: Lewandowski, E. Douglas; Carley, Andrew
  • Licensing Officer: Schultz, Teri

Thermotropic liquid crystal-based sensors for naked-eye detection of SARS-CoV-2 with ultrahigh sensitivity and selectivity
TS-063069 — In the wake of the global pandemic caused by SARS-CoV-2, the need for rapid, accurate, and efficient diagnostic methods for respiratory viral infections has become more critical than ever. Traditional diagnostic methods, while reliable, are often time-consuming, labor-intensive, and lack the neces…
  • College: College of Engineering (COE)
  • Inventors: Wang, Xiaoguang; Qin, Rongjun; Rather, Adil; Xu, Yang
  • Licensing Officer: Randhawa, Davinder

Automated Endotracheal Intubation
TS-062900 — This cutting-edge technology redefines the intubation process by guiding the endotracheal tube into the airway with exceptional precision.
The Need Intubation is a critical medical procedure used to assist patients with breathing difficulties, executed through the insertion of an endotracheal tube (ET) into the windpipe. With over 313 million annual intubation procedures worldwide, ensuring first-pass success and minimizing complicati…
  • College: College of Engineering (COE)
  • Inventors: Ruegsegger, Mark; Elsayed-Awad, Hamdy; Hopping, Ethan; Lopez Vogler, Christian; Miles, Tim; Peiffer, Jordan
  • Licensing Officer: Bhatti, Hamid

Dual-payload Humanized Antibody-Drug Conjugate (DualADC) for targeted chemo-immunotherapy
TS-062822 — Humanized Antibody-drugs conjugate for chemo-immunotherapy of multiple cancer types
The Technology Dr. Margaret Liu and colleagues have developed a dual-payload antibody-drug conjugate (DualADC) for chemo-immunotherapy utilizing a new humanized antibody that targets CD276, a surface receptor that is overexpressed in Triple-negative Breast Cancers (TNBCs), lung cancer (including non…
  • College: College of Engineering (COE)
  • Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
  • Licensing Officer: Schworer, Adam

Transforming PAH Management with PHORA: Empowering Physicians for Better Patient Care
TS-062764 — The Pulmonary Hypertension Outcomes Risk Assessment (PHORA): a PAH risk stratification tool.
Pulmonary Arterial Hypertension (PAH) demands precise risk stratification for effective patient management. Clinical decision support tools can help inform treatment decisions made by physicians and other healthcare providers, usually at the point of care. The Need Current methods for assistin…
  • College: College of Medicine (COM)
  • Inventors: Benza, Ray; Lin, Shili; Mathur, Puneet
  • Licensing Officer: Schultz, Teri

Unlocking New Frontiers in Diabetic Retinopathy Detection: Introducing Vessel Orientation-Based Quantitative OCTA Technology
TS-062762 — Pinpointing previously concealed sectoral differences in the diabetic retina to diagnose DR earlier.
Diabetic Retinopathy (DR) is a leading cause of blindness globally, requiring early and accurate diagnosis for effective intervention. The Need Current diagnostic methods for DR lack the precision needed to identify subtle retinal microvascular changes in the disease’s early stages. There i…
  • College: College of Medicine (COM)
  • Inventors: Ma, Yanhui
  • Licensing Officer: Schultz, Teri

A Breakthrough in Central Nervous System Repair
TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.
In the realm of central nervous system (CNS) repair, a critical need arises for innovative treatments that not only address the physical aspects of injury but also tackle the associated phychopathology. Understanding the cellular processes that occur after spinal cord injury (SCI) that are detrimen…
  • College: College of Medicine (COM)
  • Inventors: Tedeschi, Andrea
  • Licensing Officer: Schultz, Teri

Tracking Breast Tissue Tumor Cavity after Lumpectomy
TS-062715 — Radiopaque biodegradable polymer for the tracking of the breast tissue tumor cavity after lumpectomy and other radiation therapy applications
Approximately 40% of women diagnosed with breast cancer undergo a lumpectomy procedure. Approximately 170,000 lumpectomie are performed each yaer in the United States. Typically, this operation is followed by radiation therapy to ensure there are no remaining cancerous cells in the region. It is t…
  • College: College of Engineering (COE)
  • Inventors: Metzler, Sandra; Elisha, Deji; Evans, Izzy; Fedro, Joseph; Krakovsky, Mia; Sherry, Adam; Skoracki, Roman
  • Licensing Officer: Zinn, Ryan

Revolutionizing Vascular Access Management for Hemodialysis Patients
TS-062693 — Dynamic AVF flow control: A paradigm shift in vascular access management for hemodialysis patients.
Patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) face critical challenges in maintaining functional vascular access. Despite the superiority of arteriovenous fistulas (AVFs) in terms of longevity, infection rates, and cost-effectiveness, over a third of AVFs fail to mature a…
  • College: College of Medicine (COM)
  • Inventors: Boobes, Khaled
  • Licensing Officer: Schultz, Teri

Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males. The Need Despite the crucial role of androgen receptors (AR) in HCC progress…
  • College: College of Pharmacy
  • Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
  • Licensing Officer: Schultz, Teri

Immune Based Neuroprotective & Neuroregenerative Therapies
TS-062688 — Conditioned neutrophils and cell therapy vectors for nerve regeneration
The Need Neurological disorders arising from central nervous system (CNS) injuries and diseases pose significant challenges to quality of life. The limited capacity of CNS neurons to regenerate and the lack of effective therapies for conditions like glaucoma, optic nerve injury, and spinal cord inj…
  • College: College of Medicine (COM)
  • Inventors: Segal, Benjamin; Jerome, Andrew; Liu, Tom; Sas, Andrew
  • Licensing Officer: Bhatti, Hamid

Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Pharmacy
  • Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
  • Licensing Officer: Taysavang, Panya

E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: OSU Wexner Medical Center
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: College of Pharmacy
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Nanobody-based Protein Degraders for the Treatment of Neurodegenerative Diseases
TS-062678 — Neurodegenerative diseases including Alzheimer's and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), prion diseases, and among others affect millions of people in the US. These diseases are relentless, often fatal, and affect fundamental functions – things like moving, bre…
  • College: College of Medicine (COM)
  • Inventors: Chu, Nam; Le, Nhat
  • Licensing Officer: Taysavang, Panya

Show More Technologies

Loading icon